2-Deoxyglucose Dendrimer-Enabled Niclosamide Delivery to FRβ-Expressing Macrophages Alleviates Endometriosis Progression and Associated Hyperalgesia
A targeted niclosamide formulation reduced lesion burden and pain-associated behavior in a mouse model; human efficacy remains untested.
TL;DR
- Researchers reported a dendrimer formulation designed to deliver niclosamide to FRβ-expressing macrophages.
- In a mouse model, the formulation reduced endometriosis lesion number and volume and improved pain-associated behavior two weeks after treatment.
- The result is preclinical; the cited research does not establish safety or efficacy in people.
The study reports a targeted 2-deoxyglucose dendrimer carrying niclosamide and describes testing in a mouse model of endometriosis. The researchers report reduced lesion number and volume and improved hyperalgesia after treatment. [1]
Nature's coverage identifies the work as a mouse study and notes that replication in people would be needed before it could support a human treatment claim. Phys.org also reports the research as an early-stage, preclinical result. [2] [3]
Why it matters
The work explores a nonhormonal, targeted delivery approach in a disease area where treatment options remain limited. Its translational significance depends on follow-up evidence in people; the current result is confined to mice.
Editor's note
This is an animal study, not evidence of human benefit. TODO-review: glossary does not yet list 'endometriosis' (proposed Korean term: 자궁내막증).